Advances and Limitations of Antibody Drug Conjugates for Cancer

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Antibody drug conjugates (ADCs) are gaining prominence due to their enhanced efficacy and specificity compared to traditional chemotherapy.
• ADC success hinges on stable linkers that enable targeted payload delivery.
• Intrinsic challenges hinder optimal ADC development and clinical application.

Purpose of the Study:

• To review current marketed and approved ADCs.
• To compare linker designs and payloads utilized in ADC conjugation.
• To outline cancer-specific ADCs in late-stage clinical trials and discuss resistance mechanisms.

Main Methods:

• Literature review of marketed ADCs and clinical trial data.
• Comparative analysis of linker chemistries and payload properties.
• Exploration of resistance mechanisms and strategies for overcoming them.

Main Results:

• Summary of approved ADCs and those in late-stage development for various cancers.
• Comparison of linker stability, cleavage efficiency, and payload characteristics.
• Identification of factors influencing ADC efficacy, including drug-antibody ratio (DAR), hydrophobicity, and therapeutic index.

Conclusions:

• ADCs represent a significant advancement in cancer therapy, offering targeted treatment with improved specificity.
• Addressing challenges like drug resistance and optimizing ADC properties (DAR, hydrophobicity) are crucial for enhancing treatment outcomes.
• Continued research into novel linker designs and payloads will further expand the therapeutic potential of ADCs.